St. Jude pacing
This article was originally published in The Gray Sheet
Executive SummaryNew comorbidity indications, including syncopy and sleep apnea, are among the enhancements St. Jude hopes to add to its line of AF-suppressing, low-voltage bradycardia systems, the company tells investors during its Q1 earnings call April 17. The development is one of several initiatives to be discussed at the firm's May 1-2 analyst meeting in Minnesota. St. Jude also will discuss the launch of a porcine stented tissue valve in 2003 and may also provide further detail on the VecTor trial of the EPIC HF high-voltage resynchronization system, which is expected to gain PMA approval in 2003...
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.